Inventiva S.A. (FRA:6IVA)

Market Cap	965.20M +78.8%
Revenue (ttm)	6.76M -52.0%
Net Income	-354.14M
EPS	-1.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.820
Previous Close	3.800
Day's Range	3.820 - 4.120
52-Week Range	2.740 - 6.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 77
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6IVA

Financial Performance

In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error